Form 8-K

8-K — Turn Therapeutics Inc.

Accession: 0001213900-26-061244

Filed: 2026-05-27

Period: 2026-05-27

CIK: 0002023016

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0291866-8k_turn.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED MAY 27, 2026 (ea029186601ex99-1.htm)

GRAPHIC (ea029186601_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0291866-8k_turn.htm · Sequence: 1

false

0002023016

2026-05-27

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 27, 2026

TURN THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-42875

32-0456090

(State or other jurisdiction of

incorporation)

(Commission File Number)

(IRS Employer

Identification Number)

250 N. Westlake Blvd., Westlake Village, California

91362

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (818) 564-4011

N/A

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock, par value $0.0001 per share

TTRX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

On May 27, 2026, Turn Therapeutics

Inc. issued a press release (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current

Report on Form 8-K.

The information in Item 7.01

of this Current Report on Form 8-K and the Press Release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for

purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the

liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended,

or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release, dated May 27, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

TURN THERAPEUTICS INC.

Date: May 27, 2026

By:

/s/ Bradley Burnam

Name:

Bradley Burnam

Title:

Chief Executive Officer

EX-99.1 — PRESS RELEASE, DATED MAY 27, 2026

EX-99.1

Filename: ea029186601ex99-1.htm · Sequence: 2

Exhibit

99.1

FOR

IMMEDIATE RELEASE

Turn

Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36

Associated Inflammatory Model

● Study

demonstrates statistically significant reduction in disease severity in a murine dermatitis

model characterized by IL-36 expression

● First

in a planned series of peer-reviewed publications exploring the scientific rationale and

non-systemic mechanism underlying GX-03, currently in Phase 2 evaluation for moderate-to-severe

atopic dermatitis

LOS

ANGELES – May 27, 2026 – Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on developing

localized therapies for inflammatory and infectious skin diseases, today announced the publication of a peer-reviewed research article

in the Journal of Dermatological Treatment evaluating the effects of its lead program, GX-03, in an IL-36–associated inflammatory

environment.

The

publication, titled “Effects of extended-release topical polyhexanide in a Staphylococcus aureus-induced murine dermatitis model

characterized by IL-36 expression,” was co-authored by Bradley Burnam, Chief Executive Officer of Turn Therapeutics, and Stephen

Bresnick, M.D., a practicing physician, researcher, and advisor to the Company.

“This

publication demonstrates a shift in how inflammatory skin disease should be studied. Rather than inferring biology from systemic markers,

we evaluated GX-03 directly within an IL-36–associated inflammatory environment and observed a clear clinical effect following

seven days of twice-daily treatment,” said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. “This is about building

a more precise understanding of what is driving inflammation in the skin, at the site of disease. We’re helping define a framework

for evaluating targeted, localized therapies in dermatology.”

Study

Highlights

●

GX-03

was evaluated in a Staphylococcus aureus-induced murine dermatitis model characterized by IL-36 expression

●

IL-36

protein expression was confirmed following Staphylococcus aureus exposure, establishing the inflammatory environment in which GX-03

was evaluated

●

Mice treated

twice daily with GX-03 for seven days achieved a mean investigator global assessment score of 1.44 versus 3.00 in untreated controls

(p = 0.0003)

●

No treatment-related

adverse effects were observed

IL-36

is a cytokine associated with epithelial stress and is minimally expressed in healthy skin but becomes upregulated in response to microbial

dysbiosis and barrier disruption. The study confirmed reproducible IL-36 expression following Staphylococcus aureus exposure, establishing

a relevant inflammatory context in which GX-03 demonstrated clinical activity. This publication supports the Company’s broader

approach of targeting disease at the site of origin.

The article represents the first in a planned

series of scientific publications evaluating GX-03’s clinical and biological activity, with a subsequent manuscript already in

review characterizing the mechanistic implications of treatment.

###

About

GX-03

is a first-in-class, non-systemic, topical cytokine-modulating therapy in development for moderate-to-severe atopic dermatitis (eczema).

By stabilizing the cutaneous microenvironment and modulating epithelial danger sensing, GX-03 is designed to address IL-36, IL-4, IL-13,

and IL-31 signaling through upstream prevention rather than downstream, systemic suppression. GX-03 is currently being evaluated in a

Phase 2 randomized controlled trial, with topline results expected in mid-2026.

About

Turn Therapeutics

Turn

Therapeutics is a biotechnology company focused on developing innovative, precision therapies that target the underlying causes

of inflammatory diseases with high unmet needs. Its lead investigational therapy, GX-03, is a first-in-class, non-systemic topical inhibitor

currently in development for the treatment of moderate-to-severe atopic dermatitis. This therapy is designed to modulate key inflammatory

pathways involved in eczema and other inflammatory dermatological conditions, specifically targeting IL-36 and IL-31, two cytokines that

play distinct but interconnected roles in driving chronic skin inflammation and the itch-scratch cycle. GX-03 addresses IL-36 upstream,

where epithelial stress and barrier disruption initiate the inflammatory cascade, and IL-31 downstream, where itch signaling perpetuates

disease. It is currently being evaluated in a Phase 2 randomized controlled trial, with topline results expected in mid-2026.

Citation

Burnam

B, Bresnick S. Effects of Extended-Release Topical Polyhexanide in a Staphylococcus aureus–Induced Murine Dermatitis

Model Characterized by IL-36 Expression. Journal of Dermatological Treatment. 2026. Article ID: IJDT 2667686. DOI: https://doi.org/10.1080/09546634.2026.2667686

Forward-Looking

Statement

Certain

statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities

Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking

statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,”

“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”

“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”

“suggest,” “target,” “aim,” “should,” “will,” “would,” or the

negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking

statements are based on Turn’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are

difficult to predict, including risks related to the success of development programs, and the Company’s ability to execute its

strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate.

For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking

statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in the Company’s

filings with the Securities and Exchange Commission (the “SEC”), including the Company’s Annual Report on Form 10-K

for the year ended December 31, 2025, filed with the SEC on March 31, 2026. All such forward-looking statements speak only as of the

date they are made, and Turn undertakes no obligation to update or revise these statements, whether as a result of new information, future

events, or otherwise.

Investor

Relations / Media Contact

Sasha

Damouni

Damouni Group

LLC

Sasha@damounigroup.com

GRAPHIC

Filename: ea029186601_ex99-1img1.jpg · Sequence: 3

Binary file (5311 bytes)

Download ea029186601_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

May 27, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 27, 2026

Entity File Number

001-42875

Entity Registrant Name

TURN THERAPEUTICS INC.

Entity Central Index Key

0002023016

Entity Tax Identification Number

32-0456090

Entity Incorporation, State or Country Code

Entity Address, Address Line One

250 N. Westlake Blvd.

Entity Address, City or Town

Westlake Village

Entity Address, State or Province

Entity Address, Postal Zip Code

91362

City Area Code

818

Local Phone Number

564-4011

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

TTRX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration